Global Medical REIT Inc.

2022 was $2.2 million or three cents per share compared to $2.6 million or four cents per share in the second quarter of 2021. FFO in the second quarter was up 16% to $16.4 million and our FFO is up 17% to $17.6 million compared to the second quarter of 2021. On a per share basis, Our FFO was $0.24 per share and unit in the second quarter compared to $0.22 per share and unit in the second quarter of 2021. And the AFFO was $0.25 per share and unit up from $0.23 per share and unit in the prior year second quarter. Moving on to the balance sheet, as of June 30, 2022, our gross investment in real estate was approximately $1.4 billion, which is up $184 million from a year earlier. Relative to equity, in the second quarter, we generated gross proceeds of $1.9 million through ATM issuances at an average price of $16.24 per share. As Jeff mentioned, on Monday, we amended our credit facility to add a new $150 million delayed draw term loan component with a maturity of February 1st, 2028, extend the maturity of the revolver component to August of 2026, with two six-month company-controlled extension options, and lastly, convert all LIBOR-based loans under the facility to SOFR-based loans. This amendment enhances our liquidity and financial flexibility, and I'd like to thank our bank group for their continued support. In connection with this amendment, on Tuesday, we entered into $150 million of forward starting interest rate swaps that commence in October 2022 and mature in January 2028 that will fix the SOFR component on the new term loan through January 2028 at 2.54%. At our current leverage and including the 10 basis points spread adjustment that's associated with our conversion to SOFR-based loans, our interest rate on the new term loan will be 4.13%. At June 30th, 2022, we had approximately $660 million of gross debt. Our leverage ratio is 46.2%, and our weighted average interest rate was 3.14%. The current unutilized borrowing capacity under the credit facility is $273 million, consisting of $123 million of revolver capacity and a new $150 million delayed draw term loan. Additionally, the pro forma weighted average remaining term of our debt assuming the new term loan is drawn, is now 4.3 years. Overall, we continue to believe we are well positioned to execute on our acquisition and overall business strategy and look forward to sharing our progress with you through the balance of the year. This concludes our prepared remarks. Operator, please open the call for questions.

Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation tone indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for questions. Our first question comes from the line of Austin Werschmitt with KeyBank. Please proceed with your question.

Thanks, and good morning, everyone. Good morning, Austin. You and the team seem, you know, fairly confident in your ability to hit the acquisition goals for the year, but presumably that the leverage ratio is going to migrate towards sort of that upper threshold of your target. So I guess I'm just curious how willing are you to primarily debt fund future acquisitions and push up, you know, on that high end of the leverage range?